DiagnosDGNOF +1.00%16 PB Ratio is 44.24 as of Jul. 04, 2026, which is 27% above its 10-year median of 34.71. GuruFocus rates DGNOF with a GF Score™ of 16/100 and a GF Value™ of $0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 609 Healthcare Providers & Services companies, Diagnos ranks worse than 98.85% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-04), Diagnos's share price is $0.17695. Diagnos's Book Value per Share for the quarter that ended in Mar. 2026 was $0.00. Hence, Diagnos's PB Ratio of today is 44.24.
The historical rank and industry rank for Diagnos's PB Ratio or its related term are showing as below:
DGNOF'
s PB Ratio Range Over the Past 10 Years
Min: 5.33 Med: 34.71 Max: 220
Current: 17.7
During the past 13 years, Diagnos's highest PB Ratio was 220.00. The lowest was 5.33. And the median was 34.71.
DGNOF's PB Ratio is ranked worse than 98.85% of 609
companies
in the Healthcare Providers & Services industry
Industry Median: 1.99
vs DGNOF: 17.70
During the past 12 months, Diagnos's average Book Value Per Share Growth Rate was 200.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Diagnos was 155.20% per year. The lowest was -115.80% per year. And the median was -4.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Diagnos PB Ratio Related Terms
Diagnos PB Ratio Historical Data
* Premium members only.
The historical data trend for Diagnos's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Diagnos's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnos PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diagnos's PB Ratio distribution charts can be found below:
* The bar in red indicates where Diagnos's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Diagnos's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Diagnos (DGNOF) has a PB Ratio of 44.24 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Diagnos and its competitors. This is 27% above median its historical median of 34.71. Over the past decade, Diagnos' PB Ratio has ranged from 5.33 to 220.00. According to the industry distribution chart, Diagnos ranks #602 out of 609 companies in the Healthcare Providers & Services industry, placing it in the top 98.9%.
Is Diagnos' PB Ratio too high?
Diagnos' current PB Ratio of 44.24 is 27% above median its 10-year median of 34.71. Over the past 10 years, this metric has ranged from a low of 5.33 to a high of 220.00. The Healthcare Providers & Services industry median PB Ratio is 1.99. Diagnos' value of 44.24 is 2123.1% above this industry median. Based on the distribution chart, Diagnos ranks #602 out of 609 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Diagnos has a GF Score™ of 16/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diagnos' PB Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diagnos ranks #602 out of 609 companies for PB Ratio. This places Diagnos in the lower half of its industry. The industry median PB Ratio is 1.99. Diagnos' value of 44.24 is 2123.1% above this benchmark. Historically, Diagnos' own PB Ratio has ranged from 5.33 to 220.00 over the past decade. While the company's 10-year median is 34.71 vs. the industry median of 1.99, Diagnos has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 1.99, based on 609 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diagnos's current PB Ratio of 44.24 is 2123.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Diagnos and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnos's current PB Ratio is 44.24, which is 27% above median its own 10-year median of 34.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnos stock overvalued right now?
Based on GuruFocus' analysis, Diagnos (DGNOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.18 — trading 253.9% above its estimated fair value. The current PB Ratio is 44.24, which is 27% above median its 10-year median of 34.71 and 2123.1% above the Healthcare Providers & Services industry median of 1.99. Diagnos' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Diagnos (DGNOF), the current PB Ratio is 44.24 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diagnos (DGNOF) Overvalued in 2026?
Based on GuruFocus' analysis, Diagnos stock appears to be overvalued.
The current stock price of $0.18 is trading 253.9% above its estimated GF Value™ of $0.05.
GuruFocus considers Diagnos to be Significantly Overvalued.
Key valuation signals for DGNOF:
PB Ratio: 44.24 (27% above median its 10-year median of 34.71)
GF Value™: $0.05 vs. price of $0.18 (253.9% above fair value)
Industry Position: 2123.1% above the Healthcare Providers & Services median (#602 of 609)
No single metric tells the full story. See the DGNOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.
16GF Score
Get the complete analysis for DGNOF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DGNOF has been successfully added to your 
